Tesofensine
Tesofensine (NS2330) triple monoamine reuptake inhibitor. Inhibits SERT/NET/DAT transporters (IC₅₀ 1.7-65 nM). C₁₇H₂₃Cl₂NO, 328.28 Da, CAS 195875-84-4. ~9-day half-life. ≥98% purity. Lab research only.
From $117.80
GLP-1 & Weight Management
Research peptides for metabolic and weight management studies including GLP-1 receptor agonists, dual and triple agonists, and metabolic modulators.
Tirzepatide
- Dual Incretin Agonist: 39-residue twincretin engaging GIPR and GLP-1R, ≥98% HPLC purity
- Biased GLP-1R Signaling: Favors Gs/cAMP over β-arrestin recruitment in receptor pharmacology research
- Energy-Balance Studies: Investigational compound for metabolic-pathway and incretin biology research
From $94.05
Cagrilintide (10mg)
Cagrilintide - Long-acting amylin analog activating AMY1R/AMY2R/AMY3R and CALCR receptors. ≥98% purity (HPLC). Half-life 159-195 hours. For laboratory research only.
From $94.05
Cagri-Sema Blend (5 mg, 5 mg)
Cagrilintide 5mg / Semaglutide 5mg research blend for laboratory studies. Pharmaceutical-grade dual peptide for in-vitro research only. Not for human consumption.
From $122.55
Tirz, Cagrilintide (10 mg, 5 mg)
Cagrilintide 5mg / Tirzepatide 10mg research blend for laboratory studies. Pharmaceutical-grade peptides for in-vitro research only. Not for human consumption.
From $189.05
Semaglutide Capsules (500mcg) 25 Count
Oral semaglutide is a 31-amino acid GLP-1 receptor agonist with engineered modifications (Aib8, C-18 fatty di-acid, Lys34Arg) enabling oral bioavailability via SNAC absorption enhancement technology. Research demonstrates glycemic control comparable to injectable GLP-1 agonists with 15.1% weight loss (50mg dose, OASIS-1 trial).
From $94.05
- 1
- 2